ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO028

Assessment of Magnesium Disturbances and Clinical Characteristics in Patients With COVID-19 In São Paulo, Brazil

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Helou, Claudia Maria de Barros, Universidade de Sao Paulo Laboratorio de Pesquisa Basica em Doencas Renais, Sao Paulo, São Paulo, Brazil
  • Arantes de Oliveira, Marcia Fernanda, Universidade de Sao Paulo Laboratorio de Pesquisa Basica em Doencas Renais, Sao Paulo, São Paulo, Brazil
  • Smolentzov, Igor, Universidade de Sao Paulo Laboratorio de Pesquisa Basica em Doencas Renais, Sao Paulo, São Paulo, Brazil
  • Rodrigues, Camila Eleuterio, Universidade de Sao Paulo Laboratorio de Pesquisa Basica em Doencas Renais, Sao Paulo, São Paulo, Brazil
  • Andrade, Lucia, Universidade de Sao Paulo Laboratorio de Pesquisa Basica em Doencas Renais, Sao Paulo, São Paulo, Brazil

Group or Team Name

  • GRUPO IRA do HC-FMUSP
Background

Infection with severe acute respiratory syndrome coronavirus 2 has resulted in a global pandemic. The objective of this study was to investigate the prevalence, causes, and clinical implications of magnesium disturbances, including their possible association with treatment outcomes, among patients with COVID-19.

Methods

This cohort study was conducted at the Hospital das Clínicas, a tertiary care academic medical center in the city of São Paulo, Brazil. We included only patients diagnosed with COVID-19, and all clinical data were extracted from medical records. The patients were classified as having hypomagnesemia (HypoMg, plasma Mg ≤ 1.58 mg/dL) or hypermagnesemia (HyperMg, plasma Mg ≥ 2.55 mg/dL), and the groups were compared in terms of clinical features and outcomes. We analyzed data collected at admission, ≤ 72 h after admission, or both.

Results

We analyzed 3,777 patients. Data regarding magnesium levels were available for 3,162 of those patients, and 344 (10.9%) were found to have HyperMg (240 men and 104 women). The mean age of the HyperMg group patients was 62.2 ± 0.8 years (range, 15-98 years). Of the HyperMg group patients, 54% died during hospitalization, 86% required mechanical ventilation, 13.4% developed AKI, 4% required dialysis, and 4.3% presented cardiac arrhythmia. Comorbidities included COPD (in 6%), diabetes (in 36.6%), hypertension (in 61.5%), and cardiovascular disease (in 17%). Seven patients presented moderately high levels of Mg (> 4.0 mg/dL), and all of those patients died. Of the 344 HyperMg group patients, 97 (28%) had hypernatremia and 27 (8%) had hyponatremia. HypoMg was found in 166 (5.2%) of the patients (84 men and 82 women). The mean age of the HypoMg group patients was 59.0 ± 1.4 years (range, 18-99 years), and 23% died during hospitalization. Of the 166 HypoMg group patients, 11 (6.6%) had hypernatremia and 11 (6.6%) had hyponatremia.

Conclusion

Magnesium disturbances, especially HyperMg, appear to be common in COVID 19, increasing the risk of death. Further studies are needed in order to determine the cause of the high rate of hypermagnesemia in patients with COVID-19.

Funding

  • Government Support – Non-U.S.